EYLEA Achieved Significant Anatomic Improvements in MEfRVO

Treatment with EYLEA resulted in 2 to 3 times greater reductions in CRT compared with control

Mean change in CRT (µm) through
Month 6 from baseline1-4,*

Mean change in central retinal thickness (CRT) in Vibrant study, Chart Mean change in central retinal thickness (CRT) in Vibrant study, Chart
Mean change in central retinal thickness (CRT) in Copernicus study, Chart Mean change in central retinal thickness (CRT) in Copernicus study, Chart
Mean change in central retinal thickness (CRT) in Galileo study, Chart Mean change in central retinal thickness (CRT) in Galileo study, Chart
Anatomic measures were not used to
influence treatment decisions.5

*Last observation carried forward; full analysis set.

VIBRANT Study Design

Randomized, multicenter, double-masked, controlled study in which patients with MEfBRVO (N=181; age range: 42-94 years, with a mean of 65
years) were randomized to receive: 1) EYLEA 2 mg Q4 or 2) laser photocoagulation administered at baseline and subsequently as needed
(control group).5

The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.5

COPERNICUS and GALILEO
Study Designs

Randomized, multicenter, double-masked, sham-controlled studies in patients with MEfCRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either: 1) EYLEA 2 mg Q4 for the first 6 months or 2) sham injections (control) Q4 for a total of 6 injections.5

In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in BCVA at Week 24 compared with baseline.5

BCVA, best-corrected visual acuity; CRT, central retinal thickness; Q4, every 4 weeks.

Available in a
single-dose–strength PFS5

See dosing in MEfRVO, Button See dosing in MEfRVO, Button

EYLEA delivered powerful
visual acuity gains in MEfRVO5

View vision data, Button View vision data, Button
Enrollment form for reimbursement process, Icon
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

See the details, Button
Product support syringe, Icon
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works, Button
Downloadable resource for HCPs, Icon
Resources

Get the information you
and your patients need
about EYLEA.

See resources, Button
References
  1. Campochiaro PA, Clark WL, Boyer DS, et al. lntravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544. doi:10.1016/j.ophtha.2014.08.031
  2. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032. doi:10.1016/j.ophtha.2012.01.042
  3. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278-284. doi:10.1136/bjophthalmol-2012-301504
  4. Data on file. Regeneron Pharmaceuticals, Inc.
  5. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021